First test of marburg shot begins in humans
NCT ID NCT07425821
Summary
This is the first human study to test the safety and immune response of a new vaccine designed to protect against Marburg virus disease, a severe and often fatal illness. The trial will enroll 112 healthy adults and will carefully test four different dose levels to find the safest amount. The main goal is to see if the vaccine is well-tolerated and if it triggers an immune response that could protect against the virus.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARBURG VIRUS DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CTI Clinical Research Center
Norwood, Ohio, 45212, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
George Washington University
Washington D.C., District of Columbia, 20052, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Johnson County Clin-Trials
Lenexa, Kansas, 66219, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.